Nurix Therapeutics announces $125M common stock offering

Nurix Therapeutics announced that it has commenced an underwritten public offering of $125M of its common stock and, in lieu of common stock, in the case of certain investors, pre-funded warrants to purchase shares of its common stock. All of the securities will be offered and sold by Nurix. Nurix currently intends to use any net proceeds from this offering primarily to fund clinical development of its drug candidates, to fund research and development activities to expand its pipeline and for working capital and general corporate purposes. J.P. Morgan Securities, Piper Sandler & Co. and Stifel, Nicolaus & Company are acting as joint book-running managers for the proposed offering. Needham & Company and RBC Capital Markets are acting as lead managers for the proposed offering.